These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32380864)

  • 1. Ligelizumab for the treatment of chronic spontaneous urticaria.
    Wedi B
    Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
    Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
    Arm JP; Bottoli I; Skerjanec A; Floch D; Groenewegen A; Maahs S; Owen CE; Jones I; Lowe PJ
    Clin Exp Allergy; 2014 Nov; 44(11):1371-85. PubMed ID: 25200415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
    Staubach P; Alvaro-Lozano M; Sekerel BE; Maurer M; Ben-Shoshan M; Porter M; Hua E; Ji Y; Burciu A; Savelieva M; Severin T; Drollmann A; Bienczak A
    Pediatr Allergy Immunol; 2023 Jul; 34(7):e13982. PubMed ID: 37492920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
    Maurer M; Giménez-Arnau A; Bernstein JA; Chu CY; Danilycheva I; Hide M; Makris M; Metz M; Savic S; Sitz K; Soong W; Staubach P; Sussman G; Barve A; Burciu A; Hua E; Janocha R; Severin T
    Allergy; 2022 Jul; 77(7):2175-2184. PubMed ID: 34773261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for chronic urticaria.
    Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IgE for the Treatment of Chronic Urticaria.
    Wedi B; Traidl S
    Immunotargets Ther; 2021; 10():27-45. PubMed ID: 33628747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
    Kuo BS; Li CH; Chen JB; Shiung YY; Chu CY; Lee CH; Liu YJ; Kuo JH; Hsu C; Su HW; Li YF; Lai A; Ho YF; Cheng YN; Huang HX; Lung MC; Wu MS; Yang FH; Lin CH; Tseng W; Yang J; Lin CY; Tsai PH; Chang HK; Wang YJ; Chen T; Lynn S; Liao MJ; Wang CY
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab: a review of its use in patients with chronic spontaneous urticaria.
    McCormack PL
    Drugs; 2014 Sep; 74(14):1693-9. PubMed ID: 25217402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
    Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
    Cakmak ME
    Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab.
    Gasser P; Tarchevskaya SS; Guntern P; Brigger D; Ruppli R; Zbären N; Kleinboelting S; Heusser C; Jardetzky TS; Eggel A
    Nat Commun; 2020 Jan; 11(1):165. PubMed ID: 31913280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging treatments for chronic urticaria.
    Wedi B
    Expert Opin Investig Drugs; 2022 Mar; 31(3):281-290. PubMed ID: 35166638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.